-
1دورية أكاديمية
المؤلفون: Schwenk, Michael, Zieschang, Tania, Englert, Stefan, Grewal, Gurtej, Najafi, Bijan, Hauer, Klaus
مرشدي الرسالة: Department of Geriatric Research, Bethanien-Hospital/ Geriatric Center at the University of Heidelberg, Heidelberg, Germany, Department of Surgery, Interdisciplinary Consortium on Advanced Motion Performance (iCAMP), College of Medicine, University of Arizona, 1656 E Mabel Street, Tucson, Arizona 85724, USA, Arizona Center on Aging, University of Arizona, Tucson, USA, Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany
الإتاحة: http://hdl.handle.net/10150/610031Test
http://arizona.openrepository.com/arizona/handle/10150/610031Test -
2تقرير
المؤلفون: Siegel, Jonathan M, Weber, Hans-Jochen, Englert, Stefan
مصطلحات موضوعية: Statistics - Applications
الوصول الحر: http://arxiv.org/abs/2203.02182Test
-
3
-
4دورية أكاديمية
المصدر: Pharmaceutical Statistics ; ISSN 1539-1604 1539-1612
الإتاحة: https://doi.org/10.1002/pst.2386Test
-
5تقرير
المؤلفون: Degtyarev, Evgeny, Rufibach, Kaspar, Shentu, Yue, Yung, Godwin, Casey, Michelle, Englert, Stefan, Liu, Feng, Liu, Yi, Sailer, Oliver, Siegel, Jonathan, Sun, Steven, Tang, Rui, Zhou, Jiangxiu
المصدر: Statistics in Biopharmaceutical Research, 2020, 12(4), 427-437
مصطلحات موضوعية: Quantitative Biology - Other Quantitative Biology
الوصول الحر: http://arxiv.org/abs/2006.04480Test
-
6تقرير
المؤلفون: Meyer, R. Daniel, Ratitch, Bohdana, Wolbers, Marcel, Marchenko, Olga, Quan, Hui, Li, Daniel, Fletcher, Chrissie, Li, Xin, Wright, David, Shentu, Yue, Englert, Stefan, Shen, Wei, Dey, Jyotirmoy, Liu, Thomas, Zhou, Ming, Bohidar, Norman, Zhao, Peng-Liang, Hale, Michael
مصطلحات موضوعية: Quantitative Biology - Other Quantitative Biology
الوصول الحر: http://arxiv.org/abs/2005.10248Test
-
7دورية أكاديمية
المؤلفون: Italiano, Antoine, Cassier, Philippe A., Lin, Chia-Chi, Alanko, Tuomo, Peltola, Katriina J., Gazzah, Anas, Shiah, Her-Shyong, Calvo, Emiliano, Cervantes, Andrés, Roda, Desamparados, Tosi, Diego, Gao, Bo, Millward, Michael, Warburton, Lydia, Tanner, Minna, Englert, Stefan, Lambert, Stacie, Parikh, Apurvasena, Afar, Daniel E., Vosganian, Gregory, Moreno, Victor
المساهمون: HUS Comprehensive Cancer Center, Department of Oncology
مصطلحات موضوعية: Budigalimab, Head and neck squamous cell cancer, Non-small cell lung cancer, PD-1 inhibitor, 3122 Cancers
وصف الملف: application/pdf
العلاقة: AbbVie and the authors thank the patients who participated in this clinical trial, the study coordinators, and support staff. We would like to acknowledge James P. Sheridan (Drug Metabolism Pharmacokinetics & Bioanalysis Department, AbbVie) for performing the preclinical and clinical pharmacokinetic studies, and Fiona Harding (Oncology Discovery, AbbVie) for creating, selecting, and validating the ABBV-181 antibody and filing the in vitro/in vivo IND supporting reports, including summaries of the preclinical activity of ABBV-181. Biomarker sample testing was performed by Covance, Princeton, NJ (flow cytometry), Mosaic Laboratories, Lake Forest, CA (immunohistochemistry), and Myriad RBM, Austin, TX (cytokine testing). This study was funded by AbbVie Inc., North Chicago, IL, USA. Medical writing support was provided by Joanne Franklin, PhD, CMPP, Aptitude Health, The Hague, the Netherlands, funded by AbbVie. AbbVie and the authors thank the patients who participated in this clinical trial, the study coordinators, and support staff. We would like to acknowledge James P. Sheridan (Drug Metabolism Pharmacokinetics & Bioanalysis Department, AbbVie) for performing the preclinical and clinical pharmacokinetic studies, and Fiona Harding (Oncology Discovery, AbbVie) for creating, selecting, and validating the ABBV-181 antibody and filing the in vitro/in vivo IND supporting reports, including summaries of the preclinical activity of ABBV-181. Biomarker sample testing was performed by Covance, Princeton, NJ (flow cytometry), Mosaic Laboratories, Lake Forest, CA (immunohistochemistry), and Myriad RBM, Austin, TX (cytokine testing). This study was funded by AbbVie Inc., North Chicago, IL, USA. Medical writing support was provided by Joanne Franklin, PhD, CMPP, Aptitude Health, The Hague, the Netherlands, funded by AbbVie. Antoine Italiano: Consulting/advisory role: Roche, Daiichi Sankyo, Immune Design, Epizyme, Bayer, Lilly; honoraria: Bayer, Daiichi Sankyo, Lilly, Epizyme, Novartis, Roche; research funding: Roche, Bayer, AstraZeneca/MedImmune, PharmaMar, MSD Oncology, Merck Serono. Philippe A. Cassier: Honoraria: Novartis, Roche/Genentech, Blueprint Medicines, Amgen; research funding: Novartis, Roche/Genentech, Lilly, Blueprint Medicines, Bayer, AstraZeneca, Celgene, Plexxikon, AbbVie, Bristol-Myers Squibb, Merck Serono, Merck Sharp & Dohme; Consultancy/advisory role: Merck Serono, Roche/Genentech. Chia-Chi Lin: Consulting/advisory role: Novartis, Boehringer Ingelheim, Blueprint Medicines; travel/accommodations/expenses: Lilly, Daiichi Sankyo, BeiGene, Novartis; honoraria: Novartis, Roche, Daiichi Sankyo. Tuomo Alanko: Consulting/advisory role: Bayer, Baxalta/Shire, BMS, Celgene, Eli Lilly, MSD, Nordic Drugs, Roche, Kaiku Health; research funding: AbbVie, Bayer, Boehringer Ingelheim, BMS, Debiopharm, Eli Lilly, Incyte, MSD, Pfizer, Roche; travel/accommodations/expenses: Baxalta/Shire, BMS, MSD, Pfizer, Roche. Katriina J. Peltola: Consulting/advisory role: Orion Pharma, BMS, MSD, Novartis, Pfizer, Ipsen, Roche, Varian; stockholder: Faron Pharmaceuticals; speakers’ bureau: BMS, Pfizer, MSD; expert testimony: Ipsen; travel/accommodations/expenses: Roche, BMS; research funding: AbbVie, Bayer, BMS, MSD, Roche, Exelixis, Orion Pharma, Eisai, Novartis. Anas Gazzah: Travel, accommodations, congress registration expenses: Boehringer Ingelheim, Novartis, Pfizer, Roche; consultant/expert role: Novartis; principal/sub-investigator of clinical trials: Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X BVBA, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Aveo, Bayer HealthCare Ag, BBB Technologies BV, BeiGene, BioAlliance Pharma, BioNTech AG, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co., Clovis Oncology, Daiichi Sankyo, Debiopharm SA, Eisai, Exelixis, Forma, GamaMabs, Genentech, Inc., Gilead Sciences, Inc, GlaxoSmithKline, Glenmark Pharmaceuticals, H3 Biomedicine, Inc, F. Hoffmann-La Roche AG, Incyte Corporation, Innate Pharma, Servier IRIS, Janssen, Kura Oncology, Kyowa Kirin Pharmaceutical Development, Lilly, Loxo Oncology, Lytix Biopharma AS, MedImmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology NV, OncoEthix, OncoMed, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Pfizer, PharmaMar, Pierre Fabre, Rigontec GmbH, Roche, Sanofi Aventis, Sierra Oncology, Taiho Pharma, Tesaro, Inc, Tioma Therapeutics, Inc., Xencor; research grants: AstraZeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi; nonfinancial support (drug supplied): AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Johnson & Johnson, Lilly, MedImmune, Merck, NH TherAGuix, Pfizer, Roche. Her-Shyong Shiah: The author declares no potential conflicts of interest. Emiliano Calvo: Consulting/advisory role: Novartis, Nanobiotix, Janssen-Cilag, PsiOxus, Seattle Genetics, EUSA Pharma, AbbVie, Celgene, AstraZeneca, Guidepoint Global, Roche/Genentech, GLG, Pfizer, Servier, amcure; speakers’ bureau: Novartis; research funding: AstraZeneca, BeiGene, Novartis, START; travel/accommodations/expenses reimbursement: Roche/Genentech; honoraria: HM Hospitales Group; stock/ownership interests: START, Oncoart Associated, International Cancer Consultants; president and founder of Foundation INTHEOS . Andrés Cervantes: Institutional research funding: AbbVie, Genentech, Merck Serono, BMS, MSD, Roche, BeiGene, Bayer, Servier, Lilly, Novartis, Takeda, Astellas, FibroGen; advisory board or speaker fees: Merck Serono, Roche, Bayer, Servier, Pierre Fabre. Desamparados Roda: The author declares no potential conflicts of interest. Diego Tosi: Consulting/advisory role: BioMarin (immediate family member); research funding: Novartis, Astellas, Janssen; patent pending on a new drug combination for prostate cancer treatment; travel/accommodations/expenses: Janssen, Pfizer, Astellas Pharma; immediate family member had travel/accommodations/expenses from Nutricia and Amicus. Bo Gao: Consulting/advisory role: MSD. Michael Millward: Consulting/advisory role: Merck Sharp & Dohme, Bristol-Myers Squibb, AstraZeneca, Roche, Pfizer, Takeda, Novartis; conference travel/support: Merck Sharp & Dohme, Bristol-Myers Squibb, AstraZeneca, Roche. Lydia Warburton: Travel/accommodations/expenses: MSD, Merck. Minna Tanner: Consulting/advisory role: Roche, Novartis, Pfizer; speakers’ bureau: Roche, Novartis, Pfizer, Amgen. Gregory Vosganian: Former employee of AbbVie and may own stock. Stefan Englert, Stacie Lambert, Apurvasena Parikh, Daniel E. Afar: AbbVie employees and may own stock. Victor Moreno: Consulting fees: Merck, BMS, Janssen, Pieris; travel/accommodations: Regeneron/Sanofi; presentations: Nanobiotix; educational grant: Medscape/Bayer.; Italiano , A , Cassier , P A , Lin , C-C , Alanko , T , Peltola , K J , Gazzah , A , Shiah , H-S , Calvo , E , Cervantes , A , Roda , D , Tosi , D , Gao , B , Millward , M , Warburton , L , Tanner , M , Englert , S , Lambert , S , Parikh , A , Afar , D E , Vosganian , G & Moreno , V 2022 , ' First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma ' , Cancer Immunology, Immunotherapy , vol. 71 , no. 2 , pp. 417-431 . https://doi.org/10.1007/s00262-021-02973-wTest; 85109344549; 82232dae-2a73-44eb-98d3-0e87d81835e0; http://hdl.handle.net/10138/354706Test
-
8دورية أكاديمية
المساهمون: European Federation of Pharmaceutical Industries and Associations, EFSPI
المصدر: BMC Medicine ; volume 21, issue 1 ; ISSN 1741-7015
مصطلحات موضوعية: General Medicine
-
9
-
10